Literature DB >> 15983397

Enrichment designs: efficiency in development of cancer treatments.

Robert J Temple.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15983397     DOI： 10.1200/JCO.2005.02.913

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

Review 1.  Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?

Authors:  Peter H O'Donnell; Walter M Stadler
Journal:  Clin Cancer Res       Date:  2012-03-16       Impact factor: 12.531

Review 2.  Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer.

Authors:  Colin R Lindsay; Pavlina Spiliopoulou; Ashita Waterston
Journal:  Ther Adv Med Oncol       Date:  2015-03       Impact factor: 8.168

Review 3.  Cancer biomarkers: selecting the right drug for the right patient.

Authors:  Gary J Kelloff; Caroline C Sigman
Journal:  Nat Rev Drug Discov       Date:  2012-02-10       Impact factor: 84.694

4.  PSA decay during salvage radiotherapy for prostate cancer as a predictor of disease outcome - 5 year follow-up of a prospective observational study.

Authors:  Adalsteinn Gunnlaugsson; Elisabeth Kjellén; Ola Bratt; Göran Ahlgren; Vilberg Johannesson; René Blom; Per Nilsson
Journal:  Clin Transl Radiat Oncol       Date:  2020-05-30

5.  Advancing clinical trial design in pulmonary hypertension.

Authors:  Andy P Grieve; Shien-Chung Chow; John Curram; Stephen Dawe; Lutz O Harnisch; Noreen R Henig; Hsien Ming J Hung; D Dunbar Ivy; Steven M Kawut; Mohammad H Rahbar; Shen Xiao; Martin R Wilkins
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

6.  Dose-escalation strategies which use subgroup information.

Authors:  Amy Cotterill; Thomas Jaki
Journal:  Pharm Stat       Date:  2018-06-13       Impact factor: 1.894
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.